280 related articles for article (PubMed ID: 29981793)
1. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
Lackenby A; Besselaar TG; Daniels RS; Fry A; Gregory V; Gubareva LV; Huang W; Hurt AC; Leang SK; Lee RTC; Lo J; Lollis L; Maurer-Stroh S; Odagiri T; Pereyaslov D; Takashita E; Wang D; Zhang W; Meijer A
Antiviral Res; 2018 Sep; 157():38-46. PubMed ID: 29981793
[TBL] [Abstract][Full Text] [Related]
2. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
[TBL] [Abstract][Full Text] [Related]
3. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
Takashita E; Meijer A; Lackenby A; Gubareva L; Rebelo-de-Andrade H; Besselaar T; Fry A; Gregory V; Leang SK; Huang W; Lo J; Pereyaslov D; Siqueira MM; Wang D; Mak GC; Zhang W; Daniels RS; Hurt AC; Tashiro M
Antiviral Res; 2015 May; 117():27-38. PubMed ID: 25721488
[TBL] [Abstract][Full Text] [Related]
4. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Meijer A; Rebelo-de-Andrade H; Correia V; Besselaar T; Drager-Dayal R; Fry A; Gregory V; Gubareva L; Kageyama T; Lackenby A; Lo J; Odagiri T; Pereyaslov D; Siqueira MM; Takashita E; Tashiro M; Wang D; Wong S; Zhang W; Daniels RS; Hurt AC
Antiviral Res; 2014 Oct; 110():31-41. PubMed ID: 25043638
[TBL] [Abstract][Full Text] [Related]
5. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
[TBL] [Abstract][Full Text] [Related]
6. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.
Hurt AC; Besselaar TG; Daniels RS; Ermetal B; Fry A; Gubareva L; Huang W; Lackenby A; Lee RT; Lo J; Maurer-Stroh S; Nguyen HT; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Tashiro M; Tilmanis D; Wang D; Zhang W; Meijer A
Antiviral Res; 2016 Aug; 132():178-85. PubMed ID: 27265623
[TBL] [Abstract][Full Text] [Related]
7. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Okomo-Adhiambo M; Sleeman K; Lysén C; Nguyen HT; Xu X; Li Y; Klimov AI; Gubareva LV
Influenza Other Respir Viruses; 2013 Sep; 7(5):645-58. PubMed ID: 23575174
[TBL] [Abstract][Full Text] [Related]
8. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y
Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831
[TBL] [Abstract][Full Text] [Related]
9. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
[TBL] [Abstract][Full Text] [Related]
10. Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
Mohr PG; Williams J; Tashiro M; Streltsov VA; McKimm-Breschkin JL
Antiviral Res; 2020 Oct; 182():104895. PubMed ID: 32750469
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
13. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
Monto AS; McKimm-Breschkin JL; Macken C; Hampson AW; Hay A; Klimov A; Tashiro M; Webster RG; Aymard M; Hayden FG; Zambon M
Antimicrob Agents Chemother; 2006 Jul; 50(7):2395-402. PubMed ID: 16801417
[TBL] [Abstract][Full Text] [Related]
14. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D
J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491
[TBL] [Abstract][Full Text] [Related]
15. [Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms].
Huang L; Zhou JF; Wei H; Shu YL
Bing Du Xue Bao; 2012 Sep; 28(5):572-6. PubMed ID: 23233936
[TBL] [Abstract][Full Text] [Related]
16. Surveillance for antiviral resistance among influenza viruses circulating in Algeria during five consecutive influenza seasons (2009-2014).
Ait-Aissa A; Derrar F; Hannoun D; Gradi EA; Scaravelli D; Bouslama Z
J Med Virol; 2018 May; 90(5):844-853. PubMed ID: 29315673
[TBL] [Abstract][Full Text] [Related]
17. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.
Okomo-Adhiambo M; Sheu TG; Gubareva LV
Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):44-9. PubMed ID: 23279896
[TBL] [Abstract][Full Text] [Related]
18. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
Govorkova EA; Takashita E; Daniels RS; Fujisaki S; Presser LD; Patel MC; Huang W; Lackenby A; Nguyen HT; Pereyaslov D; Rattigan A; Brown SK; Samaan M; Subbarao K; Wong S; Wang D; Webby RJ; Yen HL; Zhang W; Meijer A; Gubareva LV
Antiviral Res; 2022 Apr; 200():105281. PubMed ID: 35292289
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
Matos AR; Resende PC; Miranda MD; Garcia CC; Caetano BC; Lopes JCO; Debur MC; Cury ALF; Vianna LA; Lima MC; Schirmer M; Gubareva L; Hurt AC; Brown DW; Siqueira MM
Antiviral Res; 2018 Jun; 154():35-43. PubMed ID: 29601892
[TBL] [Abstract][Full Text] [Related]
20. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.
Tamura D; Sugaya N; Ozawa M; Takano R; Ichikawa M; Yamazaki M; Kawakami C; Shimizu H; Uehara R; Kiso M; Kawakami E; Mitamura K; Kawaoka Y
Clin Infect Dis; 2011 Feb; 52(4):432-7. PubMed ID: 21248368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
